CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity

Isabelle Solomon, Maria Amann, Anne Goubier, +29

Nature Cancer

Cancer ImmunosurveillanceT-regulatory CellImmunologyTumor ImmunityRegulatory T Cells +8

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

Manuel Hidalgo, Maria Martinez‐García, Christophe Le Tourneau, +20

Clinical Cancer Research

Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy

Benjamin Ribba, Christophe Boetsch, Tapan K. Nayak, +9

Clinical Cancer Research

The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)

Johanna C. Bendell, Tamara Saurí, Antonio Cubillo Gracián, +23

The Oncologist

Safety, PK/PD, and anti-tumor activity of RO6874281, an engineered variant of interleukin-2 (IL-2v) targeted to tumor-associated fibroblasts via binding to fibroblast activation protein (FAP).

Morten Mau‐Sørensen, Willeke Ros, María E. Rodríguez-Ruiz, +14

Journal of Clinical Oncology

Engineered VariantImmunologyOutpatient SettingImmunoeditingImmunotherapeutics +21

Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies

Gabrielle Leclercq-Cohen, Hélène Haegel, Anneliese Schneider, +12

Journal for ImmunoTherapy of Cancer

Physiologically Based Absorption Modelling to Predict the Impact of Drug Properties on Pharmacokinetics of Bitopertin

Neil Parrott, Dominik Hainzl, Emmanuel Scheubel, +4

The AAPS Journal

Pharmacological StudyPharmacodynamicsAbsorption ModellingMedicineBioanalysis +7

Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers

Carsten Hofmann, Flavia Pizzagalli, Christophe Boetsch, +6

Psychopharmacology

Glycine Reuptake InhibitorsNeurophysiologyMedicineHealthy VolunteersCerebrospinal Fluid +6

Clinical activity and safety of simlukafusp alfa, an engineered interleukin-2 variant targeted to fibroblast activation protein-α, combined with atezolizumab in patients with recurrent or metastatic cervical cancer.

Antoîne Italiano, Loïc Verlingue, Hans Prenen, +16

Journal of Clinical Oncology

Metastatic Cervical CancerImmunologyImmunoeditingImmunotherapeuticsImmunotherapy +15

Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors

Neeltje Steeghs, Carlos Gomez‐Roca, Kristoffer Staal Rohrberg, +16

Clinical Cancer Research